Tuberculosis and HIV interaction in sub-Saharan Africa: Impact on patients and programmes; implications for policies

Tropical Medicine and International Health

Volumn 10, Issue 8, 2005, Pages 734-742

  Maher, Dermot ^a   Harries, Anthony ^b   Getahun, Haileyesus ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b MINISTRY OF HEALTH   (Malawi)

Author keywords

Acquired immunodeficiency syndrome; Africa; Human immunodeficiency virus; Policies; Programmes; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

DISEASE CONTROL; TUBERCULOSIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MONITORING; PATIENT CARE; PREVALENCE; RECURRENT DISEASE; TREATMENT OUTCOME;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CONTINUITY OF PATIENT CARE; HEALTH POLICY; HUMANS; NATIONAL HEALTH PROGRAMS; PREVALENCE; PREVENTIVE HEALTH SERVICES; QUALITY OF HEALTH CARE; RECURRENCE; TUBERCULOSIS;

AFRICA; EASTERN HEMISPHERE; SUB-SAHARAN AFRICA; WORLD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 23244451655     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2005.01456.x     Document Type: Article

References (63)

1. Aisu T, Raviglione M, Van Praag E et al. (1995) Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS 9, 267-273.
2. Anderson S & Maher D (2001) An Analysis of Interaction between TB and HIV/AIDS Programmes in Sub-Saharan Africa (WHO/CDS/TB/2001.294) World Health Organization, Geneva.
3. Angeby KA, Hoffner SE & Diwan VK (2004) Should the 'bleach microscopy method' be recommended for improved case detection of tuberculosis? Literature review and key person analysis. International Journal of Tuberculosis and Lung Disease 8, 806-815.
4. Badri M, Wilson D & Wood R (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359, 2059-2064.
5. Barry CE, Slayden RA, Sampson AE & Lee RE (2000) Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochemical Pharmacology 59, 221-231.
6. Borgdorff MW, Floyd K & Broekmans JF (2002) Interventions to reduce tuberculosis mortality and transmission in low and middle-income countries. Bulletin of the World Health Organization 80, 217-227.
7. Chimzizi RB, Harries AD, Hargreaves NJ, Kwanjana JH & Salaniponi FM (2001) Care of HIV complications in patients receiving anti-tuberculosis treatment in hospitals in Malawi. International Journal of Tuberculosis and Lung Disease 5, 979-981.
8. Coninx R, Maher D, Reyes H & Grzemska M (2000) Tuberculosis in prisons in countries with high prevalence. BMJ 320, 440-442.
9. Corbett EL, Watt CJ, Walker N et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163, 1009-1021.
10. Crampin AC, Floyd S, Mwaungulu F et al. (2001) Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. International Journal of Tuberculosis and Lung Disease 5, 994-999.
11. Crofton J (1962) The contribution of treatment to the prevention of tuberculosis. Bulletin of the International Onion against Tuberculosis 32, 643-653.
12. Currie CS, Williams BG, Cheng RC & Dye C (2003) Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS 17, 2501-2508.
13. Daley CL (1993) Tuberculosis recurrence in Africa: true relapse or re-infection? Lancet 342, 756-757.
14. DiPerri G, Cruciani M, Danzi MH et al. (1989) Nosocomial epidemic of active tuberculosis in HIV infected patients. Lancet 2, 1502-1504.
15. Dye C, Garnett GP, Sleeman K & Williams BG (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet 352, 1886-1891.
16. Dye C, Scheele S, Dolin P, Pathania V & Raviglione MC. (1999) Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. Journal of the American Medical Association 282, 677-686.
17. Elliott AM, Halwiindi B, Hayes RJ et al. (1995a) The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 89, 78-82.
18. Elliott AM, Halwiindi B, Hayes RJ et al. (1995b) The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two year follow-up of a cohort in Lusaka, Zambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 98, 9-21.
19. Elzinga G, Raviglione MC & Maher D (2004) Scale up: meeting targets in global tuberculosis control. Lancet 363, 814-819.
20. Fitzgerald DW, Desvarieux M, Severe P et al. (2000) Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 356, 1470-1474.
21. Gurumurthy P, Ramachandran G, Hemanth Kumar AK et al. (2004) Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clinical Infectious Diseases 15, 280-283.
22. Harries AD, Nyong'Onya Mbewe L, Salaniponi FM et al. (1996) Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi. Lancet 347, 807-809.
23. Harries AD, Kamenya A, Namarika D et al. (1997) Delays in diagnosis and treatment of smear-positive tuberculosis and the incidence of tuberculosis in hospital nurses in Blantyre, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 15-17.
24. Harries AD, Maher D & Nunn P (1997b) Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bulletin of the World Health Organization 75, 477-489.
25. Harries AD, Maher D & Nunn P (1998) An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high HIV prevalence settings in sub-Saharan Africa. Bulletin of the World Health Organization 76, 651-662.
26. Harries A, Hargreaves N, Kemp J et al. (2001) Deaths from TB in sub-Saharan Africa countries with a high prevalence of HIV-1. Lancet 357, 1519-1523.
27. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O & Salaniponi FM (2001b) Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358, 410-414.
28. Harries AD, Maher D & Stephen G (2004) TB/HIV: A Clinical Manual, 2nd edn (WHO/TB/2004.329). World Health Organization, Geneva.
29. Harries AD, Libamba E, Schouten EJ, Mwansambo A, Salaniponi FM & Mpazanje R (2004b) Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis. BMJ 329, 1163-1166.
30. Hawken M, Nunn P, Gathua S et al. (1993) Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 342, 332-337.
31. International Union Against Tuberculosis and Lung Disease (2000) Management of Tuberculosis. A Guide for Low Income Countries. International Union Against Tuberculosis and Lung Disease, Paris, France.
32. Jindani A, Nunn AJ & Enarson DA (2004) Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364, 1244-1251.
33. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N & Maganu E (1999) Low levels of drug-resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. International Journal of Tuberculosis and Lung Disease 3, 4-11.
34. Kivihya-Ndugga LE, van Cleeff MR, Githui WA et al. (2003) A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. International Journal of Tuberculosis and Lung Disease 7, 1163-1171.
35. Korenromp EL, Scano F, Williams BG, Dye C & Nunn P (2003) Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clinical Infectious Diseases 37, 101-112.
36. Lee JW (2003) Global health improvement and WHO: shaping the future. Lancet 362, 2083-2088.
37. Lienhardt C & Rodrigues LC (1997) Estimation of the impact of the human immunodeficiency virus infection on tuberculosis: tuberculosis risks revisited? International Journal of Tuberculosis and Lung Disease 1, 196-204.
38. Maher D, Borgdorff M & Boerma T (2005a) HIV-related tuberculosis: how well are we doing with current control efforts? International Journal of Tuberculosis and Lung Disease 9, 17-24.
39. Mäher D, Watt CJ, Williams BG, Raviglione M & Dye C (2005b) Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance? International Journal of Tuberculosis and Lung Disease 9, 123-127.
40. Mukadi YD, Maher D & Harries AD (2001) Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 15, 143-152.
41. Ngamvithayapong J, Winkvist A & Diwan V (2000) High AIDS awareness may cause tuberculosis patient delay: results from an HIV epidemic area. AIDS 14, 1413-1419.
42. Nunn P, Mungai M, Nyamwaya J et al. (1994) The effect of human immunodeficiency virus type 1 on the infectiousness of tuberculosis. Tubercle Lung Dis 75, 25-32.
43. Okwera A, Whalen C, Byekwaso F et al. (1994) Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 344, 1323-1328.
44. Perkins MD (2000) New diagnostics for tuberculosis. International Journal of Tuberculosis and Lung Disease 4, S182-S188.
45. Perriens JH, Colebunders RL, Karahunga C et al. (1991) Increased mortality and tuberculosis treatment failure among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 144, 750-755.
46. Raviglione MC, Harries AD, Msiska R, Wilkinson D & Nunn P (1997) Tuberculosis and HIV: current status in Africa. AIDS 11, S115-S123.
47. Rieder HL, Cauthen GM, Comstock GW & Snider DE (1989) Epidemiology of tuberculosis in the United States. Epidemiologic Reviews 11, 79-98.
48. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B & Godfrey-Faussett P. (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 1687-1693.
49. UNAIDS (2000) Technical Update: Voluntary Counselling and Testing, Joint United Nations programme on HIV/AIDS, Geneva.
50. UNAIDS (2004) AIDS Epidemic Update 2004. Joint United Nations programme on HIV/AIDS, Geneva.
51. WHO & UNAIDS (2000) Provisional WHO/UNAIDS Secretariat Recommendations on the Use of Cotrimoxazole Prophylaxis in Adults and Children Living with HIV/AIDS in Africa. (http://www.unaids.org/publications/documents/ care/general/ recommendation-eng.pdf) Joint United Nations Programme on HIV/AIDS, Geneva.
52. World Health Organization (1999a) Preventive therapy against tuberculosis in people living with HIV. Weekly Epidemiological Record 74, 385-398.
53. World Health Organization (1999b) Guidelines for the Prevention of Tuberculosis in Health care Facilities in Resource-limited Settings. (WHO/CDS/TB/99.269) World Health Organization, Geneva.
54. World Health Organization (2000) Fifty-third World Health Assembly. Resolutions and Decisions, Resolution WHA 53.1, Geneva, Switzerland.
55. World Health Organization (2002a) Strategic Framework to Decrease the Burden of TB/HIV, (WHO/CDS/TB/2002.296). World Health Organization, Geneva.
56. World Health Organization (2002b) World Health Report: Reducing Risks, Promoting Healthy Life. WHO, Geneva.
57. World Health Organization (2003a) Guidelines for Implementing Collaborative TB and HIV Interventions (WHO/CDS/TB/ 2003.319). World Health Organization, Geneva.
58. World Health Organization (2003b) Treatment of Tuberculosis: Guidelines for National Programmes, 3rd edn 2003 (WHO/ CDS/TB/2003.313) World Health Organization, Geneva.
59. World Health Organization (2003c) Scaling up Antiretroviral Therapy in Resource-limited Settings. Guidelines for a Public Health Approach. World Health Organization, Geneva.
60. World Health Organization (2003d) Community Contribution to TB care: Practice and Policy (WHO/CDS/TB/2003.312). World Health Organization, Geneva.
61. World Health Organization (2004a) Interim Policy on Collaborative TB/HIV Activities. (WHO/HTM/TB/2004.330). World Health Organization, Geneva.
62. World Health Organization (2004b) Global Tuberculosis Control: Surveillance, Planning and Financing. WHO, Geneva.
63. World Health Organization (2004c) Report on the Meeting of the Second ad hoc Committee on the TB epidemic, Montreux, 18-19 September 2003 (WHO/HTM/2004.28). World Health Organization, Geneva.